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Melflufen is a novel peptide–drug conjugate that rapidly delivers a cytotoxic payload into tumor cells.
It has emerged as a potential new multiple myeloma treatment, particularly for late-stage forms of the
disease. Here we describe the rationale and design of OCEAN (NCT03151811), a randomized, head-to-
head, superiority, open-label, global, Phase III study evaluating the efficacy and safety of melflufen +
dexamethasone versus pomalidomide + dexamethasone. Eligible patients with relapsed refractory mul-
tiple myeloma have received 2–4 previous treatments and are refractory to both lenalidomide and their
last treatment. Patients are excluded if they have previously received pomalidomide. The primary end-
point is progression-free survival, and key secondary endpoints include overall response rate, duration of
response and overall survival.
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Multiple myeloma
Multiple myeloma (MM) is the second most common hematological malignancy after non-Hodgkin’s lymphoma [1].
Approximately 32,110 new cases of MM were expected to be diagnosed in the USA in 2019, accounting for 1.8%
of all new cancer cases, with approximately 12,960 deaths from the disease [2,3]. It occurs at a higher rate in men
than in women and in people of African descent compared with other ethnicities [3].
Despite considerable improvements in the clinical outcomes for patients with MM in recent decades [4–6], MM
remains incurable with a high burden of disease. As the disease progresses, patients experience a repeating pattern
of remission and relapse as they cycle through therapeutic options. Each period of remission is usually shorter
than the last as the tumor becomes more aggressive [7]. Clonal evolution and genomic instability within myeloma
clones drive disease progression and treatment resistance [8–11]. When the disease becomes progressive on therapy,
or within 60 days of the last treatment, it is classified as relapsed refractory MM (RRMM) [12]. Furthermore, as
patients with MM are usually elderly (median age at diagnosis of 69 years), they often present with comorbidities
such as cardiovascular disease, diabetes and pulmonary disease, which not only further impact the patient’s quality
of life, but also limit the choice of treatment [13,14].
In recent years, multiple new treatment options have been approved for use in MM. These include the im-
munomodulatory drug (IMiD) pomalidomide, the proteasome inhibitors (PIs) carfilzomib and ixazomib, mon-
oclonal antibodies (mAbs) daratumumab and elotuzumab, and most recently, the selective inhibitor of nuclear
export, selinexor [15,16]. Although such treatments have improved clinical outcomes, treatment of patients who are
refractory to previous therapies is still challenging. A growing concern among clinicians is the increasing popula-
tion of patients who are refractory to front-line treatments, including lenalidomide and daratumumab, effectively
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Figure 1. The metabolism of melflufen. Melflufen (top left) is metabolized into melphalan (middle) and
p-Fluorophenylalanine (bottom) by aminopeptidases inside myeloma cells.
eliminating these drugs from further use. Also, patients with RRMM are highly heterogenous; therefore, the need
remains for new, efficacious drugs with novel mechanisms of action.
Melflufen
Melflufen (melphalan flufenamide) is a novel peptide–drug conjugate that rapidly delivers a cytotoxic payload
into tumor cells [17]. Melflufen is highly lipophilic, allowing it to be rapidly taken up by myeloma cells [17].
The antineoplastic activity of melflufen is dependent upon the expression of aminopeptidases, like APN (also
known as CD13), which cleave melflufen into melphalan and p-Fluorophenylalanine (Figure 1) [18,19]. Following
aminopeptidase-dependent cleavage, the hydrophilic alkylating metabolite melphalan accumulates in myeloma cells.
This enrichment of the cytotoxic payload has a substantial impact on the antimyeloma activity of melflufen [18,20].
Multiple cell culture studies of melflufen have demonstrated higher cytotoxicity in myeloma cells compared with
peripheral blood mononuclear cells, with significant activity observed in melphalan-resistant myeloma cells [19,21,22].
Indeed, melflufen-induced apoptosis is initiated after 2 h of exposure to melflufen, whereas melphalan-induced
apoptosis is initiated after 6 h of exposure [21]. This rapid cytotoxicity may explain how melflufen can overcome
melphalan-resistance in vitro and in xenograft models. In patient-derived myeloma tumor samples, melflufen
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Figure 2. The clinical development of melflufen.
Reproduced with the permission of the owner, Oncopeptides AB C©.
RRMM: relapsed refractory multiple myeloma; SoC: standard of care.
demonstrated approximately 50-fold higher cytotoxicity than melphalan, and exposure of melphalan was 50-fold
higher with melflufen versus direct administration of melphalan in culture [20,21]. Furthermore, melflufen shows
strong anti-angiogenic properties [22,23]. Finally, the first-in-human study of intravenous melflufen in solid tumors
showed that it could be administered safely at active doses with a hematologic toxicity profile as expected for an
alkylating agent [24].
Clinical development of melflufen
Melflufen has been in clinical development in multiple myeloma since 2013, as outlined here. The OCEAN study
detailed in this report builds on encouraging results from two prior studies (Figure 2): a completed Phase I/II study
(O-12-M1, NCT01897714) and an ongoing Phase II study (HORIZON, NCT02963493). Two additional
Melflufen trials have been initiated since the OCEAN study began and are currently ongoing (ANCHOR,
NCT03481556 and BRIDGE, NCT03639610; Figure 2). Finally, a Phase I/II open-label dose-escalation and
dose-expansion study of melflufen in combination with dexamethasone in patients with immunoglobulin light-
chain (AL) amyloidosis following at least one prior line of therapy is also planned to begin in 2020 (OP-102,
NCT04115956). The plasma cell dyscrasia associated with AL amyloidosis resembles that observed in MM;
therefore, therapies that are effective in MM are often used to treat AL amyloidosis. The primary endpoint of the
Phase II part of this study will be to determine overall response rate (ORR).
The Phase I part of the O-12-M1 study determined the maximum tolerated dose of melflufen as 40 mg every
21 days in combination with 40 mg dexamethasone weekly [25]; the optimal cycle length was increased from
21 to 28 days following a Phase II protocol amendment. The Phase II part assessed the activity of melflufen in
45 patients with late-stage RRMM who had received a median of four prior lines of treatment and who were
refractory to both lenalidomide (an IMiD) and bortezomib (a PI). Melflufen + dexamethasone treatment resulted
in disease stabilization in the majority of patients, with a favorable median time to next treatment and ORR [26].
Furthermore, the clinical response observed in this study was durable, which is promising given the advanced nature
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of the disease in these patients [26]. The safety profile of melflufen in the O-12-M1 study demonstrated predictable
and manageable adverse events (AEs), with the most common being grade 3 and 4 hematological AEs and low rates
of non-hematological AEs [26].
In addition to the positive results from the O-12-M1 study, the ongoing Phase II HORIZON study is assessing
the efficacy and safety of melflufen + dexamethasone in 157 patients with RRMM [27]. These patients are refractory
to pomalidomide and/or daratumumab, two of the most recently approved treatments for RRMM. Preliminary
assessment of the available data (data cutoff: 6th May 2019, n = 121) showed disease stabilization in the majority
of patients, with promising ORRs in both double- and triple-class refractory patients (including patients refractory
to the current standard of care, pomalidomide) [28]. The safety profile was comparable to that observed in the
O-12-M1 study.
Thus, the Phase I/II O-12-M1 and HORIZON studies provided preliminary evidence that melflufen is effective
in heavily pretreated patients who are refractory to various currently available therapies, having few remaining
treatment alternatives. Building on these findings, the rationale for the Phase III OCEAN study is to compare the
efficacy of melflufen to that of the current standard of care for these patients, pomalidomide. If melflufen is shown
to provide clinical benefit beyond that of pomalidomide, this may lead to the approval of melflufen for use in
patients in the real-world setting.
The OCEAN study
Introduction
OCEAN (NCT03151811) is a randomized, head-to-head, superiority, open-label, global, Phase III study evaluating
the efficacy and safety of melflufen + dexamethasone versus pomalidomide + dexamethasone in patients with MM
who have received 2–4 prior therapies; patients are refractory to both their last line of therapy and lenalidomide
within 18 months of randomization. This study is sponsored by Oncopeptides AB.
Background & study rationale
As described in detail below, enrollment in the OCEAN study required that patients with RRMM were not primary
refractory, had received at least 2–4 lines of prior therapy, and were refractory to both lenalidomide and the last
line of treatment. These patients have very few remaining treatment options and are in need of novel treatments to
improve their clinical outcomes.
Pomalidomide, a derivative of the IMiD thalidomide, is the current standard of care for patients with RRMM
who are refractory to both lenalidomide and bortezomib [29,30]. The approval of pomalidomide was based on
the Phase III study MM-003 (NIMBUS, NCT01311687), which showed that pomalidomide in combination
with low-dose dexamethasone is superior to combination with high-dose dexamethasone (median PFS of 4.0 vs
1.9 months; p < 0.0001) [31]. Many features of the OCEAN study design, such as patient population and dose
regimen, resemble those of the MM-003 study; this is to ensure that comparisons between the two studies are as
robust as possible.
The institutional review board or independent ethics committee of each investigational site approved the OCEAN
protocol. The study is being performed in accordance with the Declaration of Helsinki and Good Clinical Practice.
Study design
Eligibility criteria
Eligible patients (males and females aged ≥18 years) with RRMM must have measurable disease and received 2–4
prior lines of therapy, including lenalidomide and a PI. Patients must be refractory to both lenalidomide and the
last line of therapy, and have adequate hematologic and organ function. Patients will be excluded if they have
primary refractory disease, previously received pomalidomide, or have select comorbid conditions or residual side
effects from prior therapy above grade 1. Key eligibility criteria can be found in Box 1.
Screening
All patients must provide written informed consent before any protocol-specific screening tests or procedures
are performed. Screening is performed between days -21 and -1, when patient eligibility, baseline characteristics,
clinical assessment and disease evaluation are assessed. Of note, renal function is assessed both during the screening
process and immediately prior to study drug administration (Cycle 1, Day 1). An estimated creatine clearance
rate by Cockcroft–Gault formula of >45 ml/min is required for continuation with the study. The safety and
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Box 1. Key eligibility criteria
Key inclusion criteria
• Male or female, aged 18 years or older.
• Prior diagnosis of MM with documented disease progression in need of treatment at time of screening.
• Measurable disease defined as any of the following:
– Serum M-protein ≥0.5 g/dl by SPEP.
– Urine M-protein ≥200 mg/24 h by 24-h UPEP.
– SFLC ≥10 mg/dl and abnormal serum kappa-to-lambda free light chain ratio (SFLC ratio).
• Received 2–4 prior lines of therapy, including lenalidomide and a PI either sequentially or in the same line, and
refractory to both the last line of therapy and lenalidomide (≥10 mg) administered within 18 months prior to
randomization.
• Life expectancy of ≥6 months and an Eastern Cooperative Oncology Group performance status ≤2.
• A 12-lead ECG with QTcF interval of <470 ms.
• The following laboratory results must be met during screening (within 21 days) and immediately before study
drug administration on Cycle 1, Day 1:
– Absolute neutrophil count ≥1000 cells/mm3 (1.0 × 109/l).
– Platelet count ≥75,000 cells/mm3 (75 × 109/l).
– Hemoglobin ≥8.0 g/dl.
– Total bilirubin ≤1.5 × ULN.
– AST and ALT ≤3.0 × ULN.
– Renal function: estimated creatinine clearance by Cockcroft–Gault formula ≥45 ml/min.
Key exclusion criteria
• Primary refractory disease (i.e. never had at least minimal response to any prior therapy).
• Evidence of mucosal or internal bleeding and/or platelet transfusion refractory.
• Any medical conditions that, in the investigator’s opinion, would impose excessive risk to the patient or adversely
affect participation in the study.
• Prior exposure to pomalidomide.
• Known intolerance to IMiDs (grade ≥3 hypersensitivity reaction or at the investigator’s discretion).
• Known active infection requiring parenteral or oral anti-infective treatment within 14 days of randomization.
• Other malignancy diagnosed or requiring treatment within the past 3 years, with the exception of adequately
treated basal cell carcinoma, squamous cell skin cancer, carcinoma in situ of the cervix or breast and very low- or
low-risk prostate cancer under active surveillance.
• Concurrent symptomatic amyloidosis or plasma cell leukemia.
ECG: Eectrocardiogram; IMiD: Immunomodulatory imide drug; QTcF: QT interval calculated by Fredericia Formula; SFLC: Serum-free
light chains; SPEP: Serum protein electrophoresis; ULN: Upper limit of normal; UPEP: Urine protein electrophoresis.
pharmacokinetics of melflufen in patients with renal impairment is being assessed in the ongoing BRIDGE trial
(NCT03639610).
The cytogenetics of the patient population will be assessed by fluorescence in situ hybridization (FISH) during
screening. This will provide insight into the frequency of cytogenetic abnormalities within the study population
and may inform on the efficacy of melflufen in patients with varying degrees of cytogenetic risk.
Patients are stratified using three criteria: age (<75 vs ≥75 years); number of prior lines of treatment (2 vs 3–4);
and International Staging System score (1 vs ≥2) [32]. Prior to randomization, confirmation of patient eligibility
by the medical monitor is required. Randomization is managed by interactive response technology software and
places each patient into one of two study arms.
Treatment
Treatment is required to begin within 5 days of randomization. Each treatment cycle lasts 28 days. Patients will
only stop receiving treatment if: i) there is documented disease progression; ii) there is unacceptable toxicity; or iii)
the patient or treating physician determines that it is not in the patient’s best interest to continue.
The treatment doses and schedule are summarized in Table 1. Patients randomized to arm A will receive 40 mg
melflufen intravenously on Day 1 and 40 mg dexamethasone orally (tablets) on days 1, 8, 15 and 22 of each 28-day
cycle. Patients randomized to arm B will receive 4 mg pomalidomide capsules orally on days 1–21 and 40 mg
dexamethasone orally (tablets) on days 1, 8, 15 and 22 of each 28-day cycle. For patients aged ≥75 years, the
dexamethasone dose in both arms will be reduced from 40 mg to 20 mg on days 1, 8, 15 and 22 of each 28-day
cycle.
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Table 1. OCEAN study dose schedule.
Group Drug Dose Schedule (/28-day cycle)
Arm A Melflufen 40 mg IV Day 1
Dexamethasone 40 mg oral tablets† Days 1, 8, 15 and 22
Arm B Pomalidomide 4 mg oral capsule Days 1–21 (inclusive)
Dexamethasone 40 mg oral tablets† Days 1, 8, 15 and 22
†The dexamethasone dose will be reduced to 20 mg for patients aged ≥75 years. In the USA only, oral dexamethasone may be substituted with IV dexamethasone at the investigator’s
discretion.
IV: Intravenous.
Table 2. Required and recommended concomitant therapy.
Group(s) Concomitant therapy Comment
Required therapy
Both arms Contraception All patients of child-bearing potential from both treatment arms are required to use two
effective methods of contraception (or true abstinence, i.e. in line with the preferred and
usual lifestyle of the patient) prior to randomization. Following randomization, contraception
should be used as per protocol
Arm B Anti-thrombotic prophylactic treatment Pomalidomide treatment increases the risk of thromboembolism. Unless otherwise indicated,
patients should receive prophylactic anti-thrombotic treatment
Recommended therapy
Both arms Pneumocystic prophylaxis All patients are recommended to receive pneumocystis prophylaxis according to the NCCN or
institutional guidelines
Arm A Anti-emetic propylaxis Anti-emetic prophylaxis prior to melflufen administration is recommended. Subsequent
anti-emetic treatment is at the investigator’s discretion
Both arms Full supportive care for tumor lysis
syndrome
To include transfusions of blood and blood products (including platelets), antibiotics,
antidiarrheals, analgesics etc. and prophylactic treatment for tumor lysis syndrome when
appropriate
Both arms Bisphosphonate therapy To be administered if indicated by institutional guidelines
Both arms Supportive measures for
thrombocytopenia and neutropenia
General supportive measures, together with appropriate blood and platelet transfusions and
hematological growth factors should be administered if necessary. It is recommended, at the
investigator’s discretion, that platelet transfusion should be avoided within ≤5 days of the
next dose of study treatment (except Cycle 1, Day 1). This is to assess endogenous platelet
recovery and to avoid excessive myelosuppression. Careful attention is to be paid to
monitoring of blood counts
Both arms Anti-microbial prophylaxis Recommended for patients with a history of CMV infection and those with neutropenia,
according to the NCCN or institutional guidelines. Other anti-viral and anti-fungal treatments
are to be considered, as required
CMV: Cytomegalovirus; NCCN: National Comprehensive Cancer Network.
All required and recommended concomitant therapies for the OCEAN study are summarized in Table 2.
Follow-up
Both PFS follow-up and OS follow-up assessments should be performed. For patients who discontinue treatment
for reasons other than progression, PFS follow-up assessments will be performed. OS follow-up assessments will be
performed for all patients. Patients will only be exempt from these follow-ups in cases of death, loss to follow-up
or specific withdrawal of consent for follow-up.
Primary & secondary objectives
The primary objective of the OCEAN study is to compare the PFS of melflufen + dexamethasone and pomalido-
mide + dexamethasone, which will be assessed by the independent review committee using the IMWG consensus
response criteria [12]. Key secondary objectives include comparison of ORR, duration of response (DOR), OS, and
safety and tolerability between patients receiving melflufen + dexamethasone and those receiving pomalidomide
+ dexamethasone.
Planned study period
The first participant was randomized into the OCEAN study on 12 June 2017. The study has an estimated
completion date of Q1 2022, with the last patient in (LPI) estimated to be Q1 2020.
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Study procedures
Efficacy evaluations
In the OCEAN study, disease assessment will be performed during screening, on Cycle 1 Day 1, and on the planned
Day 1 of each cycle, even if treatment is delayed. The amount of M-protein will be determined by SPEP, UPEP or
assessment of dFLC and SFLC ratio. Immunofixation electrophoresis of both blood and urine samples will be used
to determine the type of M-protein. For patients with immunoglobulin A (IgA) or IgD myeloma, quantitative Ig
testing will also be performed because of the difficulty in assessing these disease types with SPEP [33,34]. Assessment
of dFLC and SFLC ratio is not necessary if there is measurable SPEP or UPEP but SFLC ratio is required to
confirm a stringent complete response (sCR), as defined by the IMWG criteria for diagnosis of MM [35].
In addition to M-protein assessment, disease status will be determined using skeletal x-rays and/or computed
tomography scans of bones, bone marrow aspirate, and imaging procedures of known or suspected extramedullary
plasmacytomas. These assessments, in addition to serum calcium assessment, will then be performed throughout
the study according to IMWG response criteria [11].
Safety & tolerability evaluations
AEs will be assessed and graded according to Common Terminology Criteria for Adverse Events (v4.03). Other
safety and tolerability assessments will include physical assessments (vital signs, neurological assessment and per-
formance status assessment), routine safety laboratory tests, chest x-rays, hepatitis B screens, pregnancy testing and
electrocardiograms. An independent data safety monitoring committee will regularly evaluate the risk–benefit ratio
for enrolled patients.
Pharmacokinetic evaluations
Melphalan concentrations will be determined from plasma samples for the first two treatment cycles of melflufen.
Samples will be taken at three time points following infusion: 10–15 min, 1 h and 2–4 h (as late as possible within
the time frame).
Statistical analysis
Patients are being enrolled at approximately 140 sites in 21 countries. The sample size calculation was based on the
primary objective of comparing PFS between the two arms of the study. In order to reach the target of 339 events
within 6 months after randomization of the last patient, it is anticipated that a total of 450 patients will need to be
randomized over 24 months; this is assuming a median PFS for the control arm (arm B) of 3.6 months [30]. This
design is based on a two-sided significance level of 0.05% and has a power of 90% to detect a hazard ratio of 0.70.
PFS is defined as the time (in months) from the date of randomization to the earlier of either confirmed
disease progression or death from any cause. It will be analysed by applying a two-sided, 0.05-level stratified Cox
proportional hazards regression model on the full analysis set (defined as all randomized patients). Superiority
of melflufen + dexamethasone will be demonstrated if the upper limit of the 95% confidence interval (CI) for
median PFS is below 1.0, while non-inferiority will be demonstrated if the upper limit is below 1.2. Superiority
and non-inferiority assessments are both included because the US FDA and some EU authorities have different
requirements when assessing approval for new therapies.
ORR is defined as a best confirmed response of sCR, complete response (CR), very good partial response (VGPR)
or PR using local laboratory evaluation, according to IMWG guidelines [12]. The ORR and approximate 95% CI
will be determined for each arm of the study using the Cochran–Mantel–Haenszel χ2 test. DOR is defined as the
time (in months) from the first evidence of confirmed assessment of sCR, CR, VGPR or PR to first confirmed
disease progression or death from any cause. DOR is defined only for patients with a confirmed PR or better. OS
is defined as the time (in months) from the date of randomization to death from any cause. DOR and OS will be
analysed as described for PFS. No formal statistical analysis will be performed on the safety endpoints.
Conclusion
The OCEAN study will evaluate whether melflufen is superior to pomalidomide as combination therapy with
dexamethasone for the treatment of advanced RRMM. It is hoped that this Phase III study, in conjunction with
other clinical studies of melflufen, will result in the availability of a new treatment option that will improve clinical
outcomes for patients with late-stage RRMM.
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Executive summary
Background to multiple myeloma
• Multiple myeloma (MM) is an incurable clonal B-cell malignancy of the plasma cells in bone marrow.
• Owing to clonal heterogeneity and evolution of myeloma cells, MM ultimately progresses to refractory relapsed
MM (RRMM). Patients with RRMM will typically experience diminishing periods of remission as a result of
treatment resistance.
• There is an unmet medical need for new treatments against the most aggressive and late-stage forms of RRMM.
Melflufen
• Melflufen is a novel peptide–drug conjugate that rapidly delivers a cytotoxic payload into tumor cells.
• The mechanism of action of melflufen results in the delivery of a rapid and high dose of a cytotoxic alkylator
payload to myeloma cells, attenuating the development of treatment resistance.
• The completed Phase I/II O-12-M1 study investigated the use of melflufen in patients with RRMM refractory to
both lenalidomide and bortezomib (objective response rate [ORR] 31%, duration of response 8.4 months,
progression-free survival [PFS] 5.7 months, overall survival [OS] 20.7 months).
• The ongoing Phase II HORIZON study is investigating the use of melflufen in patients with RRMM refractory to
pomalidomide and/or daratumumab (ORR 28%, PFS 4 months, OS 11.2 months [8.5 months in patients with
triple-refractory disease]).
The OCEAN study
• OCEAN is a randomized, head-to-head, superiority, open-label, global, Phase III study evaluating the efficacy and
safety of melflufen + dexamethasone versus pomalidomide + dexamethasone.
• Eligible patients are refractory to both lenalidomide and the last line of therapy, and must not have previously
received pomalidomide.
• Patients randomized to arm A will receive 40 mg melflufen intravenously on Day 1 of every cycle and 40 mg oral
dexamethasone on days 1, 8, 15 and 22 of each cycle. Patients randomized to arm B will receive 4 mg
pomalidomide capsule daily on days 1–21 of each cycle and 40 mg oral dexamethasone tablet on days 1, 8, 15 and
22 of each cycle.
• The primary endpoint is PFS.
• Secondary endpoints include OS, duration of response, ORR and safety.
Conclusion
• It is hoped that the OCEAN study will demonstrate melflufen to be superior to pomalidomide as combination
therapy with dexamethasone in patients with late-stage RRMM.
• If proved, this may lead to the availability of melflufen as a new treatment option to improve the clinical
outcomes of patients with advanced RRMM.
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